In Vivo Therapeutics Holdings is categorized under in Cambridge, MA and active since 2010.
In Vivo Therapeutics Holdings was established in 2010, and today employs 1 to 4, earning Unknown per year. This is a business, which does work in the B2B market, and is classified as a , under code number 4234501 by the NAICS.
If you are seeking more information, feel free to contact Michael Astrue, Chief Executive Officer at the company’s headquarters by writing to 1 Kendall Square, Cambridge, Massachusetts MA 02139 or by phoning (617) 863-5500. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | In Vivo Therapeutics Holdings |
| Contact Person: | Michael Astrue, Chief Executive Officer |
| Address: | 1 Kendall Square, Cambridge, Massachusetts 02139 |
| Phone Number: | (617) 863-5500 |
| Website Address: | invivotherapeutics.com |
| Annual Revenue (USD): | Unknown |
| Founded: | 2010 |
| Location Type: | Headquarters |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | |
| SIC Code: | 3841 |
| NAICS Code: | 4234501 |
| Share This Business: |
In Vivo Therapeutics Holdings was started in 2010 to provide professional under the SIC code 3841 and NAICS code 4234501. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of Unknown per annum.
Feel free to contact Michael Astrue, Chief Executive Officer for inquiries that concern In Vivo Therapeutics Holdings by calling the company number (617) 863-5500, as your correspondence is most welcome. Additionally, the physical location of the headquarters of In Vivo Therapeutics Holdings can be found at the coordinates 42.3631,-71.1033 as well as the street address 1 Kendall Square in Cambridge, Massachusetts 02139.
For its online presence, you may visit In Vivo Therapeutics Holdings’s website at invivotherapeutics.com and engage with its social media outlets through on Twitter and on Facebook.